Atropine

Enhancing National Preparedness: Rafa Laboratories Partners with BARDA to Advance the Development of a new design for Rafa's Pediatric Atropine Autoinjectors

Retrieved on: 
Wednesday, March 20, 2024
Development, Poisoning, Organophosphate, VX, Status epilepticus, Patient, Nerve agent, Clothing, Laboratory, Human services, Atropine, Sarin, Administration, FDA

Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.

Key Points: 
  • Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.
  • Rafa Laboratories already manufactures adult atropine autoinjectors, FDA-approved in July 2018, and pediatric atropine autoinjectors authorized for use under FDA Emergency Use Authorization (EUA) in January 2018.
  • The new design for the pediatric atropine autoinjector, which is intended for civilian use, will incorporate a new needle shield mechanism feature.
  • To meet FDA approval requirements for the enhanced pediatric atropine autoinjector, BARDA will provide comprehensive support to Rafa Laboratories.

Enhancing National Preparedness: Rafa Laboratories Partners with BARDA to Advance the Development of a new design for Rafa's Pediatric Atropine Autoinjectors

Retrieved on: 
Wednesday, March 20, 2024
Development, Poisoning, Organophosphate, VX, Status epilepticus, Patient, Nerve agent, Clothing, Laboratory, Human services, Atropine, Sarin, Administration, FDA

Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.

Key Points: 
  • Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.
  • Rafa Laboratories already manufactures adult atropine autoinjectors, FDA-approved in July 2018, and pediatric atropine autoinjectors authorized for use under FDA Emergency Use Authorization (EUA) in January 2018.
  • The new design for the pediatric atropine autoinjector, which is intended for civilian use, will incorporate a new needle shield mechanism feature.
  • To meet FDA approval requirements for the enhanced pediatric atropine autoinjector, BARDA will provide comprehensive support to Rafa Laboratories.

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

Retrieved on: 
Tuesday, January 16, 2024
Patient, Paratriathlon, Partnership, Near-sightedness, Acquisition, Atropine, FDA, Inflammation, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) --  Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage, ophthalmic company, today announced that it has re-acquired the rights to MicroPine in the U.S. and Canada.

Key Points: 
  • Eyenovia estimates that more than 25 million children in the U.S. suffer from myopia, and, of these, five million are believed to be at high risk for progressive myopia.
  • If left untreated, progressive myopia can ultimately lead to significant vision loss and potential blindness.
  • Our re-acquisition of the rights to MicroPine in the U.S. and Canada is consistent with our broader corporate strategy to expedite commercialization of advanced products using the Optejet.
  • This agreement has no impact on Eyenovia’s ongoing partnership with Arctic Vision, which covers development of MicroPine (as well as Mydcombi and MicroLine/Apersure) for Greater China and South Korea.

Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, Awarded Contract to Supply DuoDote®

Retrieved on: 
Tuesday, November 14, 2023
Medical Devices, Other Defense, Medical Supplies, Contracts, Chemicals, Plastics, Manufacturing, Health, Pharmaceutical, Defense, Health technology, Head, ASPR, Emergency, Meridian Medical Technologies, FDA, Infection, Antidote, Kindeva, Human services, Pralidoxime, Atropine, Administration, Hospital, CBRN, Meridian

Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services.

Key Points: 
  • Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services.
  • Meridian is a globally leading health security and chemical, biological, radiological, and nuclear (CBRN) medical countermeasure provider.
  • Meridian supplies DuoDote® to U.S. and allied ministries of health and defense, as well as hospitals and civilian first responder agencies.
  • “Meridian has a decades long history of providing medical countermeasures to military and public health agencies and civilian responders globally.

Luminopia Named to TIME’s List of the Best Inventions of 2023

Retrieved on: 
Tuesday, October 24, 2023
Software, Family, Optical, Consumer, Technology, Medical Devices, Health Technology, Clinical Trials, Children, Neurology, Audio, Video, Wearables, Mobile Technology, Health, FDA, VR, Ageing, Neuro, TIME, Invention, Entrepreneurship, Amblyopia, Virtual reality, Hospital, Paratriathlon, Eye, Algorithm, AI, Atropine, Patient, Randomized controlled trial, Pharmaceutical industry, Telescopic sight

Luminopia, Inc., a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, today announced that the company’s lead product, Luminopia, was named one of TIME’s Best Inventions of 2023.

Key Points: 
  • Luminopia, Inc., a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, today announced that the company’s lead product, Luminopia, was named one of TIME’s Best Inventions of 2023.
  • Luminopia is the first FDA-approved1 digital therapeutic for a neuro-visual disorder, indicated to improve vision in children, aged 4-7, with amblyopia (lazy eye).
  • “Despite the pace of technological advancements today, there has been little innovation in the treatment of lazy eye for several decades.
  • Of the new list, TIME’s editors shared: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)—including the world's most powerful supercomputer, a game-changing entertainment venue, and a new shape—that are changing how we live, work, play, and think about what’s possible.”
    See the full list of TIME’s Best Inventions of 2023 here: time.com/best-inventions-2023
    To learn more about Luminopia, visit luminopia.com .

Kubota Vision Announces Collaborative Research Agreement with China Medical University Hsinchu Hospital

Retrieved on: 
Thursday, September 7, 2023
Hospitals, Health, Science, Research, Optical, Near-sightedness, Arm, Safety, Atropine, Doctor of Philosophy, JAMA Ophthalmology, MD, Patient, Treatment, Clinical study design, Pharmaceutical industry, Medicinal plants, Ophthalmology

Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the execution of a collaborative research agreement between Kubota Vision and China Medical University Hsinchu Hospital, Department of Ophthalmology, for a study using Kubota Glass in Taiwan, led by Dr. Ying-Shan Chen.

Key Points: 
  • Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the execution of a collaborative research agreement between Kubota Vision and China Medical University Hsinchu Hospital, Department of Ophthalmology, for a study using Kubota Glass in Taiwan, led by Dr. Ying-Shan Chen.
  • Dr. Chen is a globally renowned leader in myopia research and treatment, serving as the chief of Ophthalmology at China Medical University Hsinchu Hospital.
  • Dr. Chen stated, “Progressive myopia poses a heavy burden to individuals and society as a whole.
  • Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.

U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure

Retrieved on: 
Tuesday, July 18, 2023
CBDP, Joint Program Executive Office Chemical and Biological Defense, CBRN, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, RAD, Slave & Otis, United States Joint Forces Command, Naloxone, ROCS, Military personnel, DOD, JPM, Acquisition, The Reconstruction (1970 film), Atropine, Poisoning, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nerve, Food, Medical imaging, Risk management, Chemical substance, Radiation

The reconstitution development contract is valued at more than $39 million over the next five years.

Key Points: 
  • The reconstitution development contract is valued at more than $39 million over the next five years.
  • Atropine sulfate injection is used for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides.
  • The DOD intends the RAD-A to be an important addition to the auto-injector products that constitute a layered defense against CBRN threats for military personnel and potentially civilian stockpiles.
  • The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the Nation’s CBRN response capability.

Raman Spectroscopy Market worth $1.1 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 17, 2023
Photon, Elixir, Quinine, Countertop, Agilent Technologies, Oxford Instruments, Automation, Atropine, Thermo Fisher Scientific, Investment, Metrohm, MCT, Maharashtra University of Health Sciences, Line-scan camera, Monitoring, Nicotine, Defense, Vitamin, Research, Alkaloid, Cocaine, Mettler Toledo, Laboratory, Quality control, Growth, Scientific method, Safety, D, Vaccine, Renishaw plc, Insulin, Infrared, COVID-19, Tablet, Real-time analyzer, Animal, SWIR, PAT, Cooling, Glass, TSI, NIR, Suppository, Urbanization, Drug development, Security, Morphine, PerkinElmer, Indium gallium arsenide, Smiths Group, Fine chemical, Medical imaging, Hyphen, Geography

Lack of development of low-cost, highly efficient Raman spectrometers

Key Points: 
  • Lack of development of low-cost, highly efficient Raman spectrometers
    Handheld & Portable Raman sub-segment in instrument segment is expected to grow at the highest CAGR of the Raman spectroscopy market during the forecast period.
  • Pharmaceuticals application is expected to account for the highest market share of the Raman spectroscopy market during the forecast period.
  • China is likely to be the fastest-growing market for Raman spectroscopy in Asia Pacific during the forecast period.
  • The rising R&D initiatives in biomedicals in China is among the leading factors fueling the growth of the Raman spectroscopy market.

Raman Spectroscopy Market worth $1.1 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 17, 2023
Photon, Elixir, Quinine, Countertop, Agilent Technologies, Oxford Instruments, Automation, Atropine, Thermo Fisher Scientific, Investment, Metrohm, MCT, Maharashtra University of Health Sciences, Line-scan camera, Monitoring, Nicotine, Defense, Vitamin, Research, Alkaloid, Cocaine, Mettler Toledo, Laboratory, Quality control, Growth, Scientific method, Safety, D, Vaccine, Renishaw plc, Insulin, Infrared, COVID-19, Tablet, Real-time analyzer, Animal, SWIR, PAT, Cooling, Glass, TSI, NIR, Suppository, Urbanization, Drug development, Security, Morphine, PerkinElmer, Indium gallium arsenide, Smiths Group, Fine chemical, Medical imaging, Hyphen, Geography

Lack of development of low-cost, highly efficient Raman spectrometers

Key Points: 
  • Lack of development of low-cost, highly efficient Raman spectrometers
    Handheld & Portable Raman sub-segment in instrument segment is expected to grow at the highest CAGR of the Raman spectroscopy market during the forecast period.
  • Pharmaceuticals application is expected to account for the highest market share of the Raman spectroscopy market during the forecast period.
  • China is likely to be the fastest-growing market for Raman spectroscopy in Asia Pacific during the forecast period.
  • The rising R&D initiatives in biomedicals in China is among the leading factors fueling the growth of the Raman spectroscopy market.

Harrow Announces Fourth Quarter and Year-End 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
Pharmaceutical, Health, Oncology, Letter, Ophthalmology, Multimedia, Optometry, BPP Law School, Acquisition, Investment, Patient, Shirin David, Transition, FDA, Pharmaceutical industry, Atropine

Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022.
  • The Company also posted its fourth quarter and year-end Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com .
  • View the full release here: https://www.businesswire.com/news/home/20230323005676/en/
    “2022 was truly a transformational year for Harrow,” said Mark L. Baum, CEO of Harrow.
  • I speak for the entire Harrow Family when I say that we are very excited – and prepared – for what 2023 (and beyond) has in store for us.”
    Fourth quarter and year-end 2022 figures of merit: